On Target Laboratories LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From On Target Laboratories LLC
Keeping Track: US FDA Oncology Approvals For Ferring’s Gene Therapy Adstiladrin And Mirati’s Targeted Therapy Krazati
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
US FDA’s Reclassification Of Certain Drugs As Devices May Be 'Seismic Event' For Some
Sponsors are receiving information requests and complete response letters as a result of the agency’s transition plan, which was made in response to the Genus v. FDA ruling. The decision's aftershocks could reshape the landscape for a number of products, attorney says.
Keeping Track: US FDA Clears On Target’s Cytalux, VBI’s PreHevbrio; Keytruda Grows In Adjuvant Melanoma
The latest FDA approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Minute Insight: FDA Approves First Fluorescent Imaging Agent For Ovarian Cancer
On Target Laboratories’ Cytalux (pafolacianine) is now approved for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
- On Target Laboratories, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.